Shots:

• The CHMP has recommended the approval of Lynparza + bevacizumab for the 1L maintenance treatment of patients with HRD+ advanced ovarian cancer. The positive opinion is based on a biomarker subgroup analysis of P-III PAOLA-1 study
• The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. for newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometroid ovarian- fallopian tube- or peritoneal cancer patients who had a complete or partial response to 1L treatment with Pt. based CT and bevacizumab
• The study resulted in 67% reduction the risk of disease progression or death- improved PFS (37.2 vs 17.7 mos.). Further results of PAOLA-1 trial demonstrated improvement in the time to second disease progression- PFS2 (50.3 vs 35.3 mos.)- presented at ESMO 2020

­ Ref: AstraZeneca | Image: New Europe